Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TSHA. Taysha Gene Therapies, Inc.’s share was trading at $5.36 as of June 9th.
Likoper/Shutterstock.com
Taysha Therapeutics (TSHA) is a clinical-stage genetic medicine company focused on developing TSHA-102 for Rett syndrome, and is viewed as a high-conviction opportunity given its regulatory progress,...
